SBS Stock Overview
Designs and manufactures automation and instrumentation solutions in the fields of in-vitro diagnostics and life sciences in Germany, European Union, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 1/6 |
| Financial Health | 4/6 |
| Dividends | 4/6 |
Stratec SE Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €27.40 |
| 52 Week High | €48.00 |
| 52 Week Low | €26.35 |
| Beta | 0.23 |
| 11 Month Change | -30.01% |
| 3 Month Change | -37.16% |
| 1 Year Change | -32.93% |
| 33 Year Change | -79.05% |
| 5 Year Change | -58.73% |
| Change since IPO | 426.62% |
Recent News & Updates
Recent updates
Shareholder Returns
| SBS | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -4.0% | 2.4% | 0.8% |
| 1Y | -32.9% | -5.0% | 9.1% |
Return vs Industry: SBS underperformed the German Medical Equipment industry which returned -5% over the past year.
Return vs Market: SBS underperformed the German Market which returned 9.1% over the past year.
Price Volatility
| SBS volatility | |
|---|---|
| SBS Average Weekly Movement | 5.5% |
| Medical Equipment Industry Average Movement | 5.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: SBS has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: SBS's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1979 | 1,462 | Marcus Wolfinger | www.stratec.com |
Stratec SE, together with its subsidiaries, designs and manufactures automation and instrumentation solutions in the fields of in-vitro diagnostics and life sciences in Germany, European Union, and internationally. It designs and manufactures automated analyzer systems for clinical diagnostics and biotechnology customers; and offers complex consumables for diagnostics and medical applications. The company was formerly known as STRATEC Biomedical AG and changed its name to Stratec SE in December 2018.
Stratec SE Fundamentals Summary
| SBS fundamental statistics | |
|---|---|
| Market cap | €334.90m |
| Earnings (TTM) | €10.01m |
| Revenue (TTM) | €250.54m |
33.4x
P/E Ratio1.3x
P/S RatioIs SBS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SBS income statement (TTM) | |
|---|---|
| Revenue | €250.54m |
| Cost of Revenue | €182.78m |
| Gross Profit | €67.75m |
| Other Expenses | €57.74m |
| Earnings | €10.01m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.82 |
| Gross Margin | 27.04% |
| Net Profit Margin | 4.00% |
| Debt/Equity Ratio | 67.0% |
How did SBS perform over the long term?
See historical performance and comparison